3 news items
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CHRS
9 May 24
, assets derecognized, transactions costs of $7.2 million and other employee transition related expenses. Net income
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
CHRS
13 Mar 24
to result in a reduction in workforce of 30% by the end of 2024, including 35 employees associated with the ophthalmology divestiture, for an estimated
Coherus BioSciences Announces New Employment Inducement Grants
CHRS
23 Feb 24
to purchase an aggregate of 170,000 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $2.59
- Prev
- 1
- Next